Life sciences companies are taking advantage of digital health and virtual trial methodologies to mitigate delays in clinical research. They are using epidemiological modelling to study and predict the potential for using real-world data to gather evidence for COVID-19 therapies. They are evolving their sales and marketing strategies to optimize the overnight shift to digital channels to connect with prescribers. Finally, SAS experts will share perspective on lessons learned and the road ahead.

Confirmed Speakers

• Matt Becker, Advisory Industry Consultant – SAS
• Sherrine Eid, Principal Industry Consultant – SAS
• Patrick Homer, Advisory Industry Consultant – SAS
• Mark Lambrecht, Director – SAS